Trial Profile

A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VT EBV (Primary)
Indications Extranodal NK-T-cell lymphoma
Focus Therapeutic Use
Sponsors ViGenCell

Most Recent Events

21 Apr 2026 According to a ViGenCell media release, results from its Phase 2 clinical study of VT-EBV-N have been selected for an oral presentation at the ASCO Annual Meeting 2026. The presentation will be delivered by Dr. Young-Woo Jeon who served as the principal investigator of the study.
26 Mar 2019 Status changed from not yet recruiting to recruiting.
15 Feb 2019 Planned initiation date changed from 18 Feb 2019 to 18 Mar 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com